Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJ0L4K
|
|||
| Drug Name |
Sutimlimab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Cold type autoimmune haemolytic anemia [ICD-11: 3A20.1] | Approved | [1] | |
| Company |
Bioverativ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Complement C1s component (C1S) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Pertussis | ||||
| Staphylococcus aureus infection | ||||
| Systemic lupus erythematosus | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| WikiPathways | Complement and Coagulation Cascades | |||
| Complement Activation, Classical Pathway | ||||
| Human Complement System | ||||
| Complement cascade | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761164. | |||
| REF 2 | Antibodies to watch in 2020. MAbs. Jan-Dec 2020;12(1):1703531. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.